Scholarlink

Background <p>Immune checkpoint inhibitors (ICIs) enhance survival rate in non-small-cell lung cancer (NSCLC), but lead to immune-related adverse events, among which checkpoint-inhibitor pneumonitis (CIP) is a leading cause of death. The utility of bronchoalveolar-lavage (BAL) lymphocytosis for diagnosing CIP and predicting its severity remains uncertain.</p> Methods <p>A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines.</p> Results <p>A total of ten studies were included in the meta-analysis, comprising a total of 168 CIP samples. The pooled estimate for BAL lymphocyte percentage was 56.43% (95% CI, 43.89–68.98, I<sup>2</sup> = 99.1%) in CIP, 14.85% (95% CI, 12.04–17.66, I<sup>2</sup> = 9.0%) in idiopathic pulmonary fibrosis (IPF), and 43.76% (95% CI, 24.43–63.09, I<sup>2</sup> = 99.3%) in NSCLC patients with no ICP or IPF. Significant differences were observed between CIP and IPF (<i>p</i> &lt; 0.0001), NSCLC patients with no ICP or IPF (<i>p</i> = 0.0024). Additionally, the BAL lymphocyte percentage varied between low-grade and high-grade CIP (SMD = -1.15, 95% CI, -2.26–-0.04, I<sup>2</sup> = 82.4%). Similar results were also calculated on the BAL lymphocyte CD4:CD8 ratio. The included studies demonstrated significant heterogeneity.</p> Conclusion <p>BAL lymphocyte percentage is elevated and CD4:CD8 ratio is reduced in NSCLC patients with CIP, with higher lymphocyte percentages associated with severe disease. A deeper understanding of the relationships between immunophenotyping, clinical factors and lymphocytosis will guide the use of BAL in the diagnose and evaluation of CIP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bronchoalveolar lavage fluid lymphocytosis in immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月6日

查看全文
  • Yaozhong Zhang,
  • Yi An,
  • Yajie Huang

摘要

Background

Immune checkpoint inhibitors (ICIs) enhance survival rate in non-small-cell lung cancer (NSCLC), but lead to immune-related adverse events, among which checkpoint-inhibitor pneumonitis (CIP) is a leading cause of death. The utility of bronchoalveolar-lavage (BAL) lymphocytosis for diagnosing CIP and predicting its severity remains uncertain.

Methods

A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines.

Results

A total of ten studies were included in the meta-analysis, comprising a total of 168 CIP samples. The pooled estimate for BAL lymphocyte percentage was 56.43% (95% CI, 43.89–68.98, I2 = 99.1%) in CIP, 14.85% (95% CI, 12.04–17.66, I2 = 9.0%) in idiopathic pulmonary fibrosis (IPF), and 43.76% (95% CI, 24.43–63.09, I2 = 99.3%) in NSCLC patients with no ICP or IPF. Significant differences were observed between CIP and IPF (p < 0.0001), NSCLC patients with no ICP or IPF (p = 0.0024). Additionally, the BAL lymphocyte percentage varied between low-grade and high-grade CIP (SMD = -1.15, 95% CI, -2.26–-0.04, I2 = 82.4%). Similar results were also calculated on the BAL lymphocyte CD4:CD8 ratio. The included studies demonstrated significant heterogeneity.

Conclusion

BAL lymphocyte percentage is elevated and CD4:CD8 ratio is reduced in NSCLC patients with CIP, with higher lymphocyte percentages associated with severe disease. A deeper understanding of the relationships between immunophenotyping, clinical factors and lymphocytosis will guide the use of BAL in the diagnose and evaluation of CIP.